8-K: NeuroOne Reports Q1 FY26 Results, Projects Strong FY26 Revenue

NeuroOne Medical Technologies Corporation reported its first quarter fiscal year 2026 financial results, showing a net loss but projecting at least $10.5 million in product revenue for fiscal year 2026, a 17% increase.

Summary

• NeuroOne reported a net loss of $1.4 million, or ($0.03) per share, for Q1 fiscal 2026, compared to net income of $1.8 million, or $0.06 per share, in Q1 fiscal 2025.
• Product revenue for Q1 fiscal 2026 was $2.9 million, a decrease from $3.3 million in Q1 fiscal 2025, primarily due to an initial stocking order from Zimmer in the prior year.
• On a sequential basis, product revenue increased 5.5% from $2.7 million in Q4 fiscal 2025.
• The company expects product revenue to reach at least $10.5 million in fiscal year 2026, an increase of at least 17% compared to $9.1 million in fiscal year 2025.
• NeuroOne successfully received FDA 510(k) Clearance for its OneRF Trigeminal Nerve Ablation System ahead of schedule and completed nine cases with all patients reportedly pain-free.
• The drug delivery system program is expected to be commercial-ready for investigational clinical or animal studies in Q3 fiscal 2026, six months ahead of schedule.
• Cash and cash equivalents stood at $3.6 million as of December 31, 2025, down from $6.6 million on September 30, 2025.
• Jason Mills was appointed to the Board of Directors in December 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong operational progress, FDA clearances, and robust FY26 revenue guidance, despite a Q1 net loss largely explained by non-recurring prior-year items and a notable decrease in cash.

Positives

• Expected product revenue of at least $10.5 million in fiscal year 2026, representing an increase of at least 17% over fiscal year 2025.
• Successfully received FDA 510(k) Clearance for OneRF Trigeminal Nerve Ablation System ahead of schedule.
• Successfully completed nine trigeminal neuralgia cases to date, with all patients reportedly pain-free.
• Advanced discussions with potential tier-one strategic partners for multiple new market systems (Trigeminal Neuralgia, Basivertebral Nerve Ablation, percutaneous paddle lead).
• Continued expansion of intellectual property portfolio with 13 issued/pending U.S. patents and 4 international patents.
• Drug delivery system targeting commercial readiness for investigational studies in Q3 fiscal 2026, six months ahead of schedule.
• Record number of ablations performed with the OneRF brain ablation system in Q1 fiscal 2026.
• Appointment of veteran medical technology executive Jason Mills to the Board of Directors in December 2025.

Negatives

• Net loss of $1.4 million in Q1 fiscal 2026, compared to net income of $1.8 million in Q1 fiscal 2025, primarily due to the absence of $3.0 million in license revenue from the prior year.
• Product revenue decreased to $2.9 million in Q1 fiscal 2026 from $3.3 million in Q1 fiscal 2025, attributed to an initial stocking order from Zimmer in the prior year.
• Cash and cash equivalents decreased significantly to $3.6 million as of December 31, 2025, from $6.6 million as of September 30, 2025.
• Product gross profit margin decreased to 54.2% in Q1 fiscal 2026 from 58.9% in Q1 fiscal 2025.

Risks

• Risks related to maintaining compliance with all Nasdaq continued listing requirements.
• Strategic partnerships may not facilitate the commercialization or market acceptance of technology due to supply chain disruptions, labor shortages, or other factors.
• Technology may not perform as expected based on results of pre-clinical and clinical trials.
• Uncertainties associated with capital requirements to achieve business objectives and the ability to raise additional funds.
• Inability to secure or retain coverage or adequate reimbursement for technology.
• Uncertainties inherent in the development process of technology.
• Risks related to changes in regulatory requirements or decisions of regulatory authorities.
• Inaccurate estimation of the size and growth potential of the markets for technology.
• Risks related to clinical trial patient enrollment and the results of clinical trials.
• Inability to protect intellectual property rights.

Future Outlook

NeuroOne expects product revenue of at least $10.5 million in fiscal year 2026, representing an increase of at least 17% over fiscal year 2025. The drug delivery system is anticipated to be commercial-ready for investigational clinical or animal studies in Q3 fiscal 2026, six months ahead of schedule. Long-term animal studies for the percutaneous paddle electrode for spinal cord stimulation are scheduled to begin in Q2 fiscal 2026, and the limited market release for the OneRF Trigeminal Nerve Ablation System is expected to conclude by the end of Q2 fiscal 2026.

Management Comments

• "The momentum we established in fiscal 2025 has accelerated into the first quarter, with progress across all target markets leveraging our OneRF platform technology."
• "With a record number of ablations performed in the first quarter of fiscal 2026, we've demonstrated the continued expansion and real-world benefits of our technology."
• "Following our FDA 510(k) clearance to treat facial pain in August, we successfully completed our first nine cases, with all patients reportedly pain free."
• "Today, we are more confident than ever in our ability to deliver technologies that offer both patient and physician benefits compared to competing systems."
• "As of today, we expect product revenue in fiscal year 2026 to be at least $10.5 million, representing an increase of at least 17% when compared to fiscal year 2025."

Industry Context

StockSavvy.ai notes that NeuroOne's focus on minimally invasive, high-definition electrode technology for neurological disorders positions it in a growing segment of the medical device industry. The successful FDA clearance for trigeminal neuralgia and the expansion into new pain management markets (lower back pain, facial pain) indicate a strategic move to diversify its product portfolio and address broader patient needs, potentially increasing its competitive footprint against larger medical technology firms.

Comparison to Industry Standards

• The successful completion of nine trigeminal neuralgia cases with reported pain-free outcomes, following FDA 510(k) clearance, demonstrates strong initial clinical adoption and efficacy for a new market entry, which is a positive indicator compared to typical early-stage product launches in the medical device sector.
• The projected 17% increase in product revenue for fiscal year 2026 to at least $10.5 million suggests a robust growth trajectory, potentially outpacing some established medical device companies that may experience more modest single-digit growth rates in mature markets.
• The expedited progress of the drug delivery system, targeting commercial readiness for investigational studies six months ahead of schedule, highlights efficient R&D execution, which can be a differentiator in the highly competitive and regulated medical technology landscape.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through projected revenue growth and pipeline advancements, but also risk from cash burn and net loss.
• Patients: Improved treatment options for neurological disorders, including facial pain and potentially lower back pain, with reported positive outcomes.
• Physicians: Access to new and advanced medical technologies for diagnosis and treatment of neurological conditions.
• Employees: Continued employment and potential growth opportunities as the company expands its product portfolio and market reach.
• Creditors: No debt outstanding as of December 31, 2025, indicating a healthy balance sheet in terms of leverage, though cash position has declined.

Next Steps

• Complete limited market release for OneRF Trigeminal Nerve Ablation System by end of Q2 fiscal 2026.
• Initiate 6-month animal study for Spinal Cord Stimulation Percutaneous Paddle Lead Program in Q2 fiscal 2026.
• Achieve commercial readiness for sEEG-Based Drug Delivery Program for investigational clinical studies or animal studies in Q3 fiscal 2026.
• Conduct second audit for ISO 13485 certification in April 2026.
• Complete first cases for post-market patient registry for OneRF brain ablation system in July 2026.
• Continue diligence discussions with potential strategic partners for various product lines.
• Establish physician advisory board to evaluate the treatment of glioblastomas for the drug delivery program.

Key Dates

Recommendation

While NeuroOne reported a net loss for Q1 FY26 and a decrease in cash, these financial results are largely explained by non-recurring items from the prior year. The company demonstrates strong operational momentum with FDA clearance ahead of schedule, successful patient cases, expansion of its intellectual property, and an expedited timeline for its drug delivery system. The projected 17% increase in product revenue for FY26 is a significant positive. However, the notable cash burn warrants caution. A 'hold' recommendation reflects the balance between the strong strategic progress and future growth potential against the current quarter's financial performance and liquidity management.

Keywords

NeuroOne, NMTC, Medical Technology, Neurological Disorders, FDA Clearance, OneRF Ablation System, Trigeminal Neuralgia, Drug Delivery System, Spinal Cord Stimulation, Basivertebral Nerve Ablation, Q1 Fiscal 2026, Financial Results, Biotech, Medical Devices